Skip to main content

CORRECTION article

Front. Endocrinol., 28 December 2021
Sec. Pediatric Endocrinology
Volume 12 - 2021 | https://doi.org/10.3389/fendo.2021.830469

Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

This article is a correction to:

  1. Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

    1. Read original article
Chengjun Sun&#x;Chengjun Sun1†Biao Lu&#x;Biao Lu2†Yu Liu&#x;Yu Liu3†Yaqin ZhangYaqin Zhang4Haiyan WeiHaiyan Wei5Xu HuXu Hu6Pei HuPei Hu7Qian ZhaoQian Zhao7Yanling LiuYanling Liu8Kan YeKan Ye9Kan WangKan Wang10Zaiyan GuZaiyan Gu11Zheng LiuZheng Liu12Jin YeJin Ye13Hongxiao ZhangHongxiao Zhang14Hong ZhuHong Zhu15Zhihong JiangZhihong Jiang16Yanjie LiuYanjie Liu17Naijun WanNaijun Wan18Chengming YanChengming Yan19Jianying YinJianying Yin20Lirong YingLirong Ying21Feng HuangFeng Huang22Qingjin YinQingjin Yin23Li XiLi Xi1Feihong Luo*Feihong Luo1*Ruoqian Cheng*Ruoqian Cheng1*
  • 1Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Children’s Hospital of Fudan University, Shanghai, China
  • 2Department of Pediatrics, General Hospital of Ningxia Medical University, Yinchuan, China
  • 3Department of Endocrine and Genetic Metabolism, Maternal and Child Health-Care Hospital in Guiyang, Guiyang, China
  • 4Department of Child Health, Maternal and Child Health Care Hospital of Hainan Province, Haikou, China
  • 5Department of Pediatric Endocrinology and Inherited Metabolic Diseases, Henan Provincial Hospital, Affiliated to Zhengzhou University, Zhengzhou, China
  • 6Department of Pediatrics, Lu’an People’s Hospital, Lu’an, China
  • 7Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, National Medical Products Administration (NMPA) Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical Pharmacokinetics and Pharmacodynamics (PK & PD) Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
  • 8Department of Pediatrics, The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 9Department of Child Health, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
  • 10Department of Pediatrics, Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
  • 11Department of Pediatrics, Jiaxing First Hospital, Jiaxing, China
  • 12Department of Pediatrics, Tai’an Maternal and Child Health Care Hospital, Tai’an, China
  • 13Department of Pediatrics, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China
  • 14Department of Pediatrics, Second Hospital of Lanzhou University, Lanzhou, China
  • 15Department of Pediatrics, The First People’s Hospital of Changzhou, Changzhou, China
  • 16Department of Pediatrics, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
  • 17Department of Pediatrics, Inner Mongolia People’s Hospital, Hohhot, China
  • 18Department of Pediatrics, Jishuitan Hospital, Beijing, China
  • 19Department of Pediatrics, Anhui Province Maternity and Child Health Hospital, Anhui Medical University Maternal and Child Health Clinic College, Hefei, China
  • 20Department of Pediatrics, Hebei General Hospital, Shijiazhuang, China
  • 21Department of Pediatrics, Cixi People’s Hospital, Cixi, China
  • 22Department of Pediatrics, Affiliated Hospital of Nantong University, Nantong, China
  • 23Department of Internal Medicine, Chengdu Children’s Specialized Hospital, Chengdu, China

A Corrigendum on:
Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

by Sun, C., Lu, B., Liu, Y., Zhang, Y., Wei, H., Hu, X., Hu, P., Zhao, Q., Liu, Y., Ye, K., Wang, K., Gu, Z., Liu, Z., Ye, J., Zhang, H., Zhu, H., Jiang, Z., Liu, Y., Wan, N., Yan, C., Yin, J., Ying, L., Huang, F., Yin, Q., Xi, L., Luo, F. and Cheng, R. (2021) Front. Endocrinol. 12:779365. doi: 10.3389/fendo.2021.779365

The second and third authors, Biao Lu and Yu Liu, were not listed as co-first-authors in the article as published originally.

The Author Contributions statement, published originally read “FL and RC conceived the study design, managed the study, conducted the data analysis, and wrote the manuscript. CS helped with the data analysis and editing of the manuscript. LX, BL, YL, YZ, HW, XH, PH, QZ, YLL, KY, KW, ZG, ZL, JY, HXZ, HZ, ZJ, YJL, NW, CY, JYY, LY, FH, and QY are site investigators and conducted the study in each participating center. All authors contributed to the article and approved the submitted version”. The corrected Author Contributions statement is as follows: “FL and RC conceived the study design, managed the study, conducted the data analysis, and wrote the manuscript. CS helped with the data analysis and editing of the manuscript. BL and YL contributed to the design of the study protocol, training of trial investigators. LX, BL, YL, YZ, HW, XH, PH, QZ, YLL, KY, KW, ZG, ZL, JY, HXZ, HZ, ZJ, YJL, NW, CY, JYY, LY, FH, and QY are site investigators and conducted the study in each participating center. All authors contributed to the article and approved the submitted version.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: growth hormone deficiency, PEGylated recombinant human growth hormone, PEG-rhGH, IGF-2, children

Citation: Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F and Cheng R (2021) Corrigendum: Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial. Front. Endocrinol. 12:830469. doi: 10.3389/fendo.2021.830469

Received: 07 December 2021; Accepted: 09 December 2021;
Published: 28 December 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Sun, Lu, Liu, Zhang, Wei, Hu, Hu, Zhao, Liu, Ye, Wang, Gu, Liu, Ye, Zhang, Zhu, Jiang, Liu, Wan, Yan, Yin, Ying, Huang, Yin, Xi, Luo and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Feihong Luo, luofh@fudan.edu.cn; Ruoqian Cheng, chengrq78@163.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.